|
JP2020033372A
|
|
Oral administration
|
|
EP3765496A1
|
|
Polypeptides based on a novel scaffold
|
|
US2018305437A1
|
|
Polypeptide
|
|
MX2018005399A
|
|
New polypeptide having affinity to pd-l1.
|
|
US2018057551A1
|
|
Alzheimer abeta peptide binding polypeptide
|
|
KR20170116023A
|
|
IL-17A-binding polypeptide
|
|
WO2016059068A1
|
|
Vegfr-2 binding polypeptides
|
|
WO2016059057A1
|
|
Vegfr-2 binding polypeptides
|
|
KR20170054440A
|
|
New polypeptides
|
|
ZA201506407B
|
|
New polypeptides
|
|
US2017114099A1
|
|
Polypeptide
|
|
WO2015189431A1
|
|
New polypeptide
|
|
IL238184D0
|
|
Abd binding polypeptide and a composition comprising the polypeptide and a detectable agent
|
|
US2016311863A1
|
|
Engineered albumin binding polypeptide
|
|
WO2015028550A1
|
|
Binding polypeptides having a mutated scaffold
|
|
WO2014140366A1
|
|
New polypeptides
|
|
US2016289337A1
|
|
Polypeptides
|
|
WO2014076179A1
|
|
New polypeptide
|
|
WO2014076177A1
|
|
New polypeptide
|
|
CN104854127A
|
|
Abd binding polypeptide
|
